FDA's Oncology Center of Excellence streams its Conversations on Cancer series live and free — , beginning 3:00 p.m. ET on YouTube — with a panel on how CURE ID, FDA and NIH's crowdsourced drug-repurposing registry, can help find new treatment options for rare cancers.
Dates and format
- Date: 17 November 2026, beginning 3:00 p.m. ET
- Format: free public webcast, live on YouTube, posted afterward for on-demand viewing
- Organizer: FDA Oncology Center of Excellence (OCE), part of the Conversations on Cancer series
- No registration or fee stated
What it covers
CURE ID is a treatment registry FDA built with NIH's National Center for Advancing Translational Sciences (NCATS) to collect real-world reports of treatment experiences with repurposed drugs — submitted directly by patients, caregivers and clinicians. Fewer than 5% of the more than 10,000 known rare diseases have an FDA-approved treatment, and repurposing an already-approved drug can cost a fraction of de novo development. This session's panelists walk through how CURE ID actually works, why every submitted case report matters to the registry's usefulness, and how that crowdsourced real-world data can point toward new treatment options specifically for rare cancers.
Who should attend
Rare-disease and oncology regulatory affairs teams, patient advocacy organizations, and clinicians who treat rare cancers and might contribute case reports to CURE ID themselves. The session is free, requires no registration, and streams live on YouTube with an on-demand recording to follow. FDA's Bayesian draft guidance webinar covers a different CDER initiative the same season, its Pediatric Advisory Committee takes up child-focused safety issues, and the full events directory lists everything we have verified.
Frequently asked questions
When is FDA's Conversations on Cancer session on CURE ID?
17 November 2026, beginning 3:00 p.m. Eastern Time, as a free public webcast on YouTube.
What is CURE ID?
CURE ID is a free treatment registry developed by FDA and NIH's National Center for Advancing Translational Sciences (NCATS) that collects real-world reports of treatment experiences with repurposed drugs from patients, caregivers and clinicians.
What will the session cover?
Panelists discuss how CURE ID works, why every submitted case report matters, and how crowdsourced data can help accelerate development of new treatments for rare cancers.
Is there a fee or registration required?
No. The webcast is free of charge and streams live on YouTube; FDA also plans to post it afterward for on-demand viewing.
Sources & further reading
- FDA Oncology Center of Excellence. OCE Meetings and Workshops — Conversations on Cancer: How CURE ID Can Help Find New Treatment Options for Rare Cancers, November 17, 2026. fda.gov
- FDA Oncology Center of Excellence. Conversations on Cancer (program page). fda.gov
Event details are published by the organizer and can change. This listing was verified via WebSearch corroboration of FDA's own program pages rather than a direct fetch, because this session's network egress could not reach fda.gov directly, and the specific event sub-page (if one exists) could not be independently located — confirm details with FDA before making plans. Last verified 28 September 2026.
